Pending re-registration accounts for inconsistency in Auditor Gen. report – FDA CEO

Pending re-registration accounts for inconsistency in Auditor Gen. report – FDA CEO

- in General News, Top Story
FDA CEO, Mrs Delese Mimi DarkoFDA CEO, Mrs Delese Mimi Darko

The Acting CEO of the Food and Drugs Authority (FDA), Delese Mimi Darko, has clarified the inconsistency in the FDA’s drug registration system as recorded by the Auditor General’s Department, stating that it is due to a pending re-registration process and that the products are of good quality.

“Clients sometimes fail to re-register their product three months before the expiry date, as recommended. If a client brings a container load of drugs before they reach expiry date of the registration, the product is a valid product and cannot be removed from the market,” she explained.

She however admitted to the failure of her outfit to supervise pharmaceutical companies who manufacture drugs that are not registered in the FDA’s registration system but assured that the Authority would better its operations.

“We will bite hard in terms of supervision of the pharmaceutical companies,” she promised.


Madam Delese also accepted the accusation of the Public Accounts Committee (PAC) of Parliament of not being on top of many issues as is expected of her outfit, thereby risking the lives of Ghanaians.

She pointed out that the lack of funds contributed to their inability to acquire ware houses for the storage of detained products.

“We are putting up a structure at Tema which will have adequate space to store detained drugs and put them under good condition, as soon as we have enough funding,” she further explained.

Story by: Diana Nana Ekua Acquah Haynes (Level 300 JN A)

About the author

Leave a Reply

Your email address will not be published. Required fields are marked *